Prolonged allogeneic marrow engraftment following nonmyeloablative conditioning using 100 cGy total body irradiation and pentostatin before and pharmacological immunosuppression after transplantation

Transplantation

Volumn 80, Issue 10, 2005, Pages 1518-1521

  Panse, Jens P ^a   Storb, Rainer ^a,b   Storer, Barry ^a,b   Santos, Erlinda B ^a   Wentzel, Collette ^a   Sandmaier, Brenda M ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Hematopoietic cell transplantation; Nonmyeloablative; Pentostatin

Indexed keywords

ADENOSINE DEAMINASE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHIMERA; CONTROLLED STUDY; DOG; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; TRANSPLANTATION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADENOSINE DEAMINASE; ANIMALS; BONE MARROW TRANSPLANTATION; CYCLOSPORINE; DOGS; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; LYMPHOPENIA; MYCOPHENOLIC ACID; PENTOSTATIN; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 29144440059     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000181168.42461.0b     Document Type: Article

References (22)

1. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048-3054.
2. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
3. Storb R, Yu C, McSweeney P. Mixed chimerism after transplantation of allogeneic hematopoietic cells. In: Hematopoietic Cell Transplantation, 2nd Edition, Thomas, ED, Blume KG, Forman SJ, eds. Boston: Blackwell Science, 1999.
4. Storb R, Yu C, Barnett T, et al. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 1999; 94: 1131-1136.
5. Martin PJ. The role of donor lymphoid cells in allogeneic marrow engraftment. Bone Marrow Transplant 1990; 6: 283-289.
6. VanBuskirk AM, Pidwell DJ, Adams PW, Orosz CG. Transplantation immunology. JAMA 1997; 278: 1993-1999.
7. Vogelsang GB, Hess AD. Graft-versus-host disease: new directions for a persistent problem. Blood 1994; 84: 2061-2067.
8. Brogden RN, Sorkin EM. Pentostatin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders. Drugs 1993; 46: 652-677.
9. Van der Weyden MB, Kelley WN. Human adenosine deaminase. Distribution and properties. J Biol Chem 1976; 251: 5448-5456.
10. Aye MT, Dunne JV. Effect of 2′-deoxycoformycin on erythroid, granulocytic, and T-lymphocyte colony growth. Blood 1981; 58: 1043-1046.
11. n polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting. Transplantation 1994; 58: 701-706.
12. Denkers E, Badger CC, Ledbetter JA, Bernstein ID. Influence of antibody isotype on passive serotherapy of lymphoma. J Immunol 1985; 135: 2183-2186.
13. Moore PF, Rossitto PV, Danilenko DM, et al. Monoclonal antibodies specific for canine CD4 and CD8 define functional T-lymphocyte subsets and high density expression of CD4 by canine neutrophils. Tissue Antigens 1992; 40: 75-85.
14. Rodman LE, Farnell DR, Coyne JM, et al. Toxicity of cordycepin in combination with the adenosine deaminase inhibitor 2′-deoxycoformycin in beagle dogs. Toxicol Appl Pharmacol 1997; 147: 39-45.
15. Pavletic SZ, Bociek RG, Foran JM, et al. Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation. Transplantation 2003; 76: 877-881.
16. Grever MR, Siaw MF, Jacob WF, et al. The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 1981; 57: 406-417.
17. Zaucha JM, Yu C, Zellmer E, et al. Extending the duration of postgrafting cyclosporine (CSP) but not substituting GCSF mobilized peripheral blood mononuclear cells (G-PBMC) for marrow enhances allogeneic engraftment in a nonmyeloablative canine transplant model. Blood 2000; 96 (Part 1): 763a, 3301.
18. Storb R, Yu C, Zaucha JM, et al. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood 1999; 94: 2523-2529.
19. Hovi T, Smyth JF, Allison AC, Williams SC. Role of adenosine deaminase in lymphocyte proliferation. Clin Exp Immunol 1976; 23: 395-403.
20. Seto S, Carrera CJ, Kubota M, et al. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 1985; 75: 377-383.
21. Seto S, Carrera CJ, Wasson DB, Carson DA. Inhibition of DNA repair by deoxyadenosine in resting human lymphocytes. J Immunol 1986; 136: 2839-2843.
22. Buhler LH, Spitzer TR, Sykes M, et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002; 74: 1405-1409.